Managing Contraceptive Pill Patients, 17th Edition (Softcover)


plus s/h


ISBN Number 978-0-929240-98-5

Click Here for the 17th Edition Digital Version



The news in the 17th edition is decreased estrogen.  In 1977 the first edition of Managing Contraceptive Pill Patients listed 29 pills, 20 of which contained 50 mcg of estrogen – nearly 70%.  The book was 100 pages in length, and offered 35 references.  More than four decades later there are 150 pills in the 17th edition, but only five contain 50 mcg of estrogen.  Ever-evolving research has been the standard for this resource, and is detailed in 673 references.

The new 17th Edition offers an analysis of each new pill listed in 18 tables, as well as other hormonal contraceptive delivery systems.  Included are:

  • 4 intrauterine delivery systems
  • 3 injectables
  • 2 vaginal rings, and
  • 1 skin patch and 1 implant.

The unique center-indexed format of the first edition was revolutionary in sharing an exhaustive quantity of medical data in tables and narrative.  “The Pill” was a relatively new product in 1977.  First released in 1960, patients and providers needed comprehensive, clear information that would ensure comfort, protection and continued use.

The Sixteenth Edition of MCPP also included guidance on hormone replacement therapy.  The additional content was valued by our clients, but it was decided that focus on new hormonal contraception data was needed in 2021.


What’s Inside?


Up-dated data about oral contraceptives (OCs) is the primary feature but expanded comprehensive product information and guidance about HORMONE REPLACEMENT THERAPY makes the new edition the most wide-ranging analysis and evaluation available on hormonal balance during a woman’s life cycle.


  • Important new data about low-dose estrogen pills
  • 8 all-important tables have been revised, updated, and re-designed to define estrogen and progesterone activity
  • 140 new OCs to include:
    • 93 combination Progesterone/Estrogen pills
    • Composition of OCs with detailed regimens. i.e., mono 14-21-28 days and extended cycle – 84 or 96 days
  • More than 40 pills have been discontinued since the publication of the 15th Edition
  • Dr. Dickey’s research confirms that the greatest increase of note has been in the number of non-brand-name pharmaceutical companies, while 16 established companies continue to offer reliable new products.
The same, careful attention has been applied to the expanded and separate Hormone Replacement Therapy Section in the new edition.
  • The addition of current research and revised tables provide an easy access view of new products
  • The application and appropriate use of new treatments
  • Dr. Dickey has enhanced his original concepts of matching individual patient characteristics to products designed to relieve hormonal imbalance during a woman’s life cycle.